Rosemary, sage could boost brain health: Study
The study released in the Antioxidants journal shows a compound shared by the two herbs called carnosic acid has antioxidant and anti-inflammatory properties that shield brain cells from damage similar to what can lead to Alzheimer's. Researchers were able to create a more stable form of carnosic acid called diAcCA.
Screen time a symptom, cause of emotional distress in kids: Study
In preclinical studies, the researchers found that the compound improved memory, boosted brain synapses and reduced harmful Alzheimer's-related proteins like amyloid-beta and tau.
The diAcCA compound only activates in inflamed brain regions, which could minimize side effects. To date, studies in mice have shown significant cognitive improvements and no signs of toxicity. Researchers are looking to start human trials soon.
Researchers also believe diAcCA could help treat other inflammatory conditions, such as Type 2 diabetes, cardiovascular disease and Parkinson's disease.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nicotine poisoning rises in babies and toddlers: Study
(NewsNation) — Poison control centers are sounding the alarm on nicotine pouches as the number of young children accidentally ingesting them rises. According to a study published in the medical journal Pediatrics, calls to poison control centers that involved children under the age of 6 with nicotine poisoning rose by over 760% between 2020 and 2023. Nearly all cases happened at home. While cases included chewing tobacco, vapes and nicotine replacements such as gum and lozenges, authors of the study pointed to the rising popularity of flavored nicotine pouches as the driving force behind accidental nicotine poisonings. Bed bugs: What to know, how to treat them The levels of nicotine in pouches can vary from 3 to 12 milligrams per pouch. At the lowest doses, it can release more nicotine than a cigarette, and even that small amount can be dangerous to children. Some minor symptoms of nicotine poisoning include nausea and vomiting, but as the dose increases, more serious side effects include high blood pressure and a fast heart rate, which can lead to seizures and respiratory failure. Although the vast majority of nicotine ingestions in children resulted in little to no harm, the study found that more than 1,600 children had serious medical outcomes. Two 1-year-old boys died after ingesting liquid nicotine. To keep children safe, the study authors recommend not using nicotine pouches in front of children so they don't imitate the behavior, and keeping them out of reach. If they ingest a nicotine pouch, the best thing to do is call Poison Control at 1-800-222-1222. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Business Wire
an hour ago
- Business Wire
Simulations Plus Invests in Clinical Development Technology Company Nurocor
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor. Nurocor offers a cloud-based software platform designed to improve efficiency, reusability, governance, and automation for pharmaceutical companies through digitalization in the clinical development phase. Its solution significantly accelerates the typical clinical trial lifecycle, resulting in a reduction of the overall cost of the clinical development process. The investment was made as part of Simulations Plus' Corporate Development Initiative, launched in 2024 to support early-stage technology companies accelerating innovations within the pharmaceutical industry. 'We are pleased to support Nurocor in its mission to help clients leverage technology to bring drugs to market more rapidly,' said Shawn O'Connor, Chief Executive Officer of Simulations Plus. 'Their vision aligns with our own, and we see tremendous potential for clients to deploy our complementary solutions in clinical trial design, protocol development, and site competency and compliance. We believe our investment in Nurocor will deliver considerable and measurable value to clients and ultimately get much-needed treatments to patients faster.' 'We are excited to make this strategic investment through our Corporate Development Initiative,' said Will Frederick, Chief Financial Officer of Simulations Plus. 'This initiative is specifically designed to foster growth for early-stage companies, as well as identify potential partners and acquisition targets that complement our organic growth strategy and expand our total addressable market.' In 2024, the clinical trial technology and services sector—which encompasses digital tools and services—was estimated at $25.7 billion. It is projected to grow at a compound annual growth rate (CAGR) of 15.5% from 2025 to 2030, driven by the increasing adoption of digital health technologies and the growing demand for more efficient patient recruitment. 'We are thrilled to have the support of Simulations Plus as we enter our next stage of growth,' said Alex Lazar, Chief Executive Officer of Nurocor. 'The investment is a strong vote of confidence in our team and technology, and we look forward to partnering with them to help clients realize efficiencies through the optimization and automation of their clinical trials.' Interested parties can learn more about Simulations Plus' Corporate Development Initiative here. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will', 'can', 'believe', 'expect,' 'anticipate' and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. ###
Yahoo
an hour ago
- Yahoo
Simulations Plus Invests in Clinical Development Technology Company Nurocor
Investment to accelerate innovations in biopharma development through Corporate Development Initiative RESEARCH TRIANGLE PARK, N.C., July 14, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor. Founded in 2017, Nurocor offers a cloud-based software platform designed to improve efficiency, reusability, governance, and automation for pharmaceutical companies through digitalization in the clinical development phase. Its solution significantly accelerates the typical clinical trial lifecycle, resulting in a reduction of the overall cost of the clinical development process. The investment was made as part of Simulations Plus' Corporate Development Initiative, launched in 2024 to support early-stage technology companies accelerating innovations within the pharmaceutical industry. "We are pleased to support Nurocor in its mission to help clients leverage technology to bring drugs to market more rapidly," said Shawn O'Connor, Chief Executive Officer of Simulations Plus. "Their vision aligns with our own, and we see tremendous potential for clients to deploy our complementary solutions in clinical trial design, protocol development, and site competency and compliance. We believe our investment in Nurocor will deliver considerable and measurable value to clients and ultimately get much-needed treatments to patients faster." "We are excited to make this strategic investment through our Corporate Development Initiative," said Will Frederick, Chief Financial Officer of Simulations Plus. "This initiative is specifically designed to foster growth for early-stage companies, as well as identify potential partners and acquisition targets that complement our organic growth strategy and expand our total addressable market." In 2024, the clinical trial technology and services sector—which encompasses digital tools and services—was estimated at $25.7 billion. It is projected to grow at a compound annual growth rate (CAGR) of 15.5% from 2025 to 2030, driven by the increasing adoption of digital health technologies and the growing demand for more efficient patient recruitment. "We are thrilled to have the support of Simulations Plus as we enter our next stage of growth," said Alex Lazar, Chief Executive Officer of Nurocor. "The investment is a strong vote of confidence in our team and technology, and we look forward to partnering with them to help clients realize efficiencies through the optimization and automation of their clinical trials." Interested parties can learn more about Simulations Plus' Corporate Development Initiative here. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. ### View source version on Contacts Financial Profiles Lisa Fortuna310-622-8251slp@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
